We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Loss of Tumor Suppressor Gene Spurs Growth of Some Malignant Melanomas

By LabMedica International staff writers
Posted on 17 Nov 2015
Print article
Image: Metastatic melanoma tumors. The micrograph on the left shows low or absent expression of RASA2, which is linked to reduced survival of about 35% of patients. The sample on the right exhibits high RASA2 expression and increased survival (Photo courtesy of the Weizmann Institute of Science).
Image: Metastatic melanoma tumors. The micrograph on the left shows low or absent expression of RASA2, which is linked to reduced survival of about 35% of patients. The sample on the right exhibits high RASA2 expression and increased survival (Photo courtesy of the Weizmann Institute of Science).
Cancer researchers have identified a tumor suppressor gene that when damaged or lost acts to spur growth and spread of a subset of human malignant melanomas.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) reviewed data that had been accumulated during the genome and exome analysis of 501melanoma specimens. They reported in the October 26, 2015, online edition of the journal Nature Genetics that the RASA2 (RAS p21 protein activator 2) gene, which encodes a RasGAP (Ras GTPase activating protein), functioned as a tumor-suppressor gene that was mutated in 5% of melanomas.

The protein encoded by RASA2 is located in the cytoplasm and is part of the GAP1 family of GTPase-activating proteins. The gene product stimulates the GTPase activity of normal RAS p21 but not its cancer-promoting counterpart. Acting as a suppressor of RAS function, the protein enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP-bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated with cancer formation.

Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth, and migration. RASA2 expression was lost in more than 30% of human melanomas and was associated with reduced patient survival.

"As the RAS pathway is highly dysregulated in cancer, the discovery of an alternative mechanism for its activation is likely to stimulate an avalanche of further research in this field, and is highly likely to have direct clinical relevance. We are now going to focus on RASA2, to find out what proteins it communicates with in healthy cells and melanoma, as well as in the cells' response to targeted therapy," said senior author Dr. Yardena Samuels, professor of molecular cell biology at the Weizmann Institute of Science.

Related Links:

Weizmann Institute of Science


Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Silver Member
Static Concentrator
BJP 10
New
Progesterone Serum Assay
Progesterone ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.